-transparent.png){kind=logo}
A saturated fat meal was given to 10 normal males both before and after pretreatment with UK38,485, a thromboxane synthetase inhibitor (Dazmegrel, Pfizer Central Research, Sandwich, Kent, United Kingdom). Following the fat meal at 2 and 4 hr there was laboratory evidence of platelet activation. Dazmegrel lowered baseline platelet activity and lessened platelet activation following the fat meal. This drug should be investigated further as a potential antithrombotic agent.
Related Publications
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
December 1989,
Prostaglandins, leukotrienes, and essential fatty acids,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
May 1986,
The American review of respiratory disease,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
November 1988,
Journal of chromatography,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
November 1991,
Transplantation,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
April 1988,
Transplantation proceedings,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
June 1988,
Transplantation proceedings,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
January 1979,
Thrombosis research,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
July 1986,
British journal of plastic surgery,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
July 1982,
Journal of neurosurgery,
J J Belch, and
A R Saniabadi, and
K McLaughlin, and
C D Forbes
May 1986,
Pediatric research,
